Terms: = Endocrine gland cancer AND KDR, VEGFR2, 3791, ENSG00000128052, P35968, VEGFR, CD309, FLK1 AND Treatment
263 results:
1. Combined inhibition of HER2 and vegfr synergistically improves therapeutic efficacy via PI3K-AKT pathway in advanced ovarian cancer.
Li W; Zhang K; Wang W; Liu Y; Huang J; Zheng M; Li L; Zhang X; Xu M; Chen G; Wang L; Zhang S
J Exp Clin Cancer Res; 2024 Feb; 43(1):56. PubMed ID: 38403634
[TBL] [Abstract] [Full Text] [Related]
2. Anti-tumorigenic effects of naive and TLR4-primed adipose-derived mesenchymal stem cells on pancreatic ductal adenocarcinoma cells.
Kaçaroğlu D; Yaylacı S; Gurbuz N
Cancer Med; 2024 Jan; 13(2):e6964. PubMed ID: 38379331
[TBL] [Abstract] [Full Text] [Related]
3. Prevalence and management of proteinuria associated with vascular endothelial growth factor receptor-targeted tyrosine kinase inhibitor treatment in advanced renal cell carcinoma, hepatocellular carcinoma, and thyroid cancer.
Kato T; Mizuno R; Miyake H
Int J Urol; 2024 May; 31(5):465-474. PubMed ID: 38318663
[TBL] [Abstract] [Full Text] [Related]
4. Efficacy and safety of VEGF/vegfr inhibitors for platinum-resistant ovarian cancer: a systematic review and meta-analysis of randomized controlled trials.
Huang D; Ke L; Cui H; Li S; Sun F
BMC Womens Health; 2024 Jan; 24(1):34. PubMed ID: 38218775
[TBL] [Abstract] [Full Text] [Related]
5. The importance of early-stage blood pressure control in thyroid cancer patients treated with lenvatinib from the perspective of dose intensity.
Masaki C; Shioya J; Sugino K; Terasawa Y; Yokotsuka S; Nakata M; Kitagawa W; Ito K
Support Care Cancer; 2023 Nov; 31(12):729. PubMed ID: 38017341
[TBL] [Abstract] [Full Text] [Related]
6. Early Increases in Blood Pressure and Major Adverse Cardiovascular Events in Patients With Renal Cell Carcinoma and Thyroid cancer Treated With vegfr TKIs.
Narayan V; Liu T; Song Y; Mitchell J; Sicks J; Gareen I; Sun L; Denduluri S; Fisher C; Manikowski J; Wojtowicz M; Vadakara J; Haas N; Margulies KB; Ky B
J Natl Compr Canc Netw; 2023 Oct; 21(10):1039-1049.e10. PubMed ID: 37856199
[TBL] [Abstract] [Full Text] [Related]
7. Dynamic contrast-enhanced MRI to characterize angiogenesis in primary epithelial ovarian cancer: An exploratory study.
Lindgren A; Anttila M; Arponen O; Hämäläinen K; Könönen M; Vanninen R; Sallinen H
Eur J Radiol; 2023 Aug; 165():110925. PubMed ID: 37320880
[TBL] [Abstract] [Full Text] [Related]
8. Mass Spectrometry-Based Proteomics of Epithelial Ovarian cancers: A Clinical Perspective.
Qian L; Sun R; Xue Z; Guo T
Mol Cell Proteomics; 2023 Jul; 22(7):100578. PubMed ID: 37209814
[TBL] [Abstract] [Full Text] [Related]
9. Angiogenesis inhibitors for the treatment of epithelial ovarian cancer.
Gaitskell K; Rogozińska E; Platt S; Chen Y; Abd El Aziz M; Tattersall A; Morrison J
Cochrane Database Syst Rev; 2023 Apr; 4(4):CD007930. PubMed ID: 37185961
[TBL] [Abstract] [Full Text] [Related]
10. A multicenter, open-label, randomized, phase II study of cediranib with or without lenalidomide in iodine 131-refractory differentiated thyroid cancer.
Rosenberg AJ; Liao CY; Karrison T; de Souza JA; Worden FP; Libao B; Krzyzanowska MK; Hayes DN; Winquist E; Saloura V; Prescott K; Villaflor VM; Seiwert TY; Schechter RB; Stadler WM; Cohen EEW; Vokes EE
Ann Oncol; 2023 Aug; 34(8):714-722. PubMed ID: 37182801
[TBL] [Abstract] [Full Text] [Related]
11. Molecular cluster mining of high-grade serous ovarian cancer via multi-omics data analysis aids precise medicine.
Cai D; Liu T; Fang J; Liu Y
J Cancer Res Clin Oncol; 2023 Sep; 149(11):9151-9165. PubMed ID: 37178426
[TBL] [Abstract] [Full Text] [Related]
12. Population Pharmacokinetics and Exposure-Response Analysis for the Phase 3 COSMIC-311 Trial of Cabozantinib for Radioiodine-Refractory Differentiated Thyroid cancer.
Ly NS; Li J; Faggioni R; Roskos LK; Brose MS
Clin Pharmacokinet; 2023 Apr; 62(4):587-598. PubMed ID: 36869986
[TBL] [Abstract] [Full Text] [Related]
13. Observation of the therapeutic effect of apatinib in advanced platinum-resistant recurrent epithelial ovarian cancer.
Pan Z; Luo Z; He H; Chen Y; Zhao B; Yang Z; Li L
J Ovarian Res; 2023 Feb; 16(1):44. PubMed ID: 36823642
[TBL] [Abstract] [Full Text] [Related]
14. An angiogenic tumor phenotype predicts poor prognosis in ovarian cancer.
Wieser V; Tsibulak I; Reimer DU; Zeimet AG; Fiegl H; Hackl H; Marth C
Gynecol Oncol; 2023 Mar; 170():290-299. PubMed ID: 36758419
[TBL] [Abstract] [Full Text] [Related]
15. Synthesis of Palladium-Catalysed C-C Bond Forming 5-Chloro Quinolines via Suzuki-Miyaura Coupling; Anti-Pancreatic cancer Screening on PANC-1 Cell Lines.
Rahman A; Ningegowda NB; Siddappa MK; Pargi M; Kumaraswamy HM; Satyanarayan ND; Achur R
Chem Biodivers; 2023 Jan; 20(1):e202200622. PubMed ID: 36437502
[TBL] [Abstract] [Full Text] [Related]
16. Carboplatin enhances lymphocyte-endothelial interactions to promote CD8
Mark J; Fisher DT; Kim M; Emmons T; Khan ANMN; Alqassim E; Singel K; Mistarz A; Lugade A; Zhan H; Yu H; Segal B; Lele S; Frederick P; Kozbor D; Skitzki J; Odunsi K
Gynecol Oncol; 2023 Jan; 168():92-99. PubMed ID: 36410228
[TBL] [Abstract] [Full Text] [Related]
17. Case Report: Anlotinib combined with PD-1 inhibitor and sequential GA regimen or FOLFIRINOX Chemotherapy in treatment of KRAS G12V mutated pancreatic ductal adenocarcinoma with liver metastasis: A case and literature review.
Wang Y; Wang B; Xiang L; Deng J; Xu B; He P; Pu W; Wang H; Fan Y; Chen H
Front Immunol; 2022; 13():1016647. PubMed ID: 36311715
[TBL] [Abstract] [Full Text] [Related]
18. Maximum Value on Arterial Phase Computed Tomography Predicts Prognosis and treatment Efficacy of Sunitinib for Pancreatic Neuroendocrine Tumours.
Chen H; Li Z; Hu Y; Xu X; Ye Z; Lou X; Zhang W; Gao H; Qin Y; Zhang Y; Chen X; Chen J; Tang W; Yu X; Ji S
Ann Surg Oncol; 2023 May; 30(5):2988-2998. PubMed ID: 36310316
[TBL] [Abstract] [Full Text] [Related]
19. Integrated proteogenomic characterization across major histological types of pituitary neuroendocrine tumors.
Zhang F; Zhang Q; Zhu J; Yao B; Ma C; Qiao N; He S; Ye Z; Wang Y; Han R; Feng J; Wang Y; Qin Z; Ma Z; Li K; Zhang Y; Tian S; Chen Z; Tan S; Wu Y; Ran P; Wang Y; Ding C; Zhao Y
Cell Res; 2022 Dec; 32(12):1047-1067. PubMed ID: 36307579
[TBL] [Abstract] [Full Text] [Related]
20. Anlotinib combined with TQB2450 in patients with platinum-resistant or -refractory ovarian cancer: A multi-center, single-arm, phase 1b trial.
Lan CY; Zhao J; Yang F; Xiong Y; Li R; Huang Y; Wang J; Liu C; Bi XH; Jin HH; Meng J; Zhao WH; Zhang L; Wang YF; Zheng M; Huang X
Cell Rep Med; 2022 Jul; 3(7):100689. PubMed ID: 35858589
[TBL] [Abstract] [Full Text] [Related]
[Next]
